{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:26:04Z","timestamp":1793741164347,"version":"4.6.1"},"reference-count":40,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"unspecified","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"The redGPS Foundation is the promoter of this work with its own funds and with financial support from NOVO NORDISK PHARMA S.A."}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,8,29]]},"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n<jats:title>Objective<\/jats:title>\n<jats:p>To estimate the frequency of antidiabetic prescriptions in type 2 diabetes mellitus (T2DM) in Spain and describe changes in prescription patterns between 2018\u20132022 and 2023-2024.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Design<\/jats:title>\n<jats:p>Observational study.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Participants<\/jats:title>\n<jats:p>Patients from primary care centres newly diagnosed with T2DM in 2018\u20132022 and 2023\u20132024.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Primary and secondary outcomes<\/jats:title>\n<jats:p>In each period, the prescription frequency of an antidiabetic medication at the diagnosis of T2DM was calculated and subsequently subdivided into monotherapy and combination therapy. The prescription frequency of the most common antidiabetic drugs was also calculated. Calculations were made for the entire group of subjects and stratified by sex and age (under 60 years and 60 years or older). Comparison of the frequencies between the two periods was performed using the chi-square test.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>In 2018\u20132022 and 2023\u20132024, 78.4% and 88.9% of patients, respectively, were prescribed an antidiabetic medication. The prescription frequencies for monotherapy and combination therapy were 66.1% and 33.9% in the first period and 57.4% and 42.6% in the second. The prescription frequencies for metformin as monotherapy and combination therapy were 57.4% and 27.8% in the first period and 46.6% and 39.8% in the second. Prescribing metformin with sodium-glucose cotransporter-2 inhibitors (SGLT2i) and\/or glucagon-like peptide receptor 1 agonists (GLP1a) was the most frequent combination therapy: 12.8% in 2018\u20132022 and 29.5% in 2023\u20132024. With a few exceptions, the prescribing pattern was similar by sex and age. The difference between the prescribing distributions in the two periods is significant.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Antidiabetic medication prescribing at the diagnosis of T2DM was high. Most prescriptions contained metformin. Monotherapy decreased in 2023\u20132024 compared with 2018\u20132022, while combination therapy increased due to increased prescriptions of metformin with SGLT2i and\/or GLP1a.<\/jats:p>\n<\/jats:sec>","DOI":"10.1136\/bmjopen-2025-106069","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:46:50Z","timestamp":1758638810000},"page":"e106069","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Changes in prescription patterns of antidiabetic medication in patients newly diagnosed with type 2 diabetes in Spain: an observational study"],"prefix":"10.1136","volume":"15","author":[{"given":"Lucia","family":"Cea-Soriano","sequence":"first","affiliation":[{"name":"CIBERESP, Madrid, Community of Madrid, Spain"},{"name":"Public Health & Maternal and Child Health, Universidad Complutense de Madrid, Madrid, Comunidad de Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6841-2050","authenticated-orcid":false,"given":"Almudena","family":"Moreno","sequence":"additional","affiliation":[{"name":"Public Health & Maternal and Child Health, Universidad Complutense de Madrid, Madrid, Comunidad de Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Calonge","sequence":"additional","affiliation":[{"name":"Centre d\u2019Atenci\u00f3 Prim\u00e0ria Arb\u00facies, Girona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rivas","sequence":"additional","affiliation":[{"name":"Centro de Salud de San Sebasti\u00e1n, Santa Cruz de Tenerife, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Pulido-Manzanero","sequence":"additional","affiliation":[{"name":"CIBERESP, Madrid, Community of Madrid, Spain"},{"name":"Public Health & Maternal and Child Health, Universidad Complutense de Madrid, Madrid, Comunidad de Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Constanza","family":"Colchero","sequence":"additional","affiliation":[{"name":"Centro de Salud Amante Laff\u00f3n, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Artola","sequence":"additional","affiliation":[{"name":"Primary Care Centre Jos\u00e9 Marv\u00e1, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Serrano","sequence":"additional","affiliation":[{"name":"Centro de Salud Mart\u00edn de Vargas, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Franch-Nadal","sequence":"additional","affiliation":[{"name":"BASIQ- USR, DAP-Cat group. Unitat de Suport a la Recerca Barcelona Ciutat, Institut Universitari d\u2019Investigaci\u00f3 en Atenci\u00f3 Prim\u00e0ria Jordi Gol (IDIAP Jordi Gol), Barcelona, Spain"},{"name":"Primary Health Care Center Raval Sud, Ger\u00e8ncia d\u2019\u00c0mbit d\u2019Atenci\u00f3 Prim\u00e0ria Barcelona Ciutat, Institut Catal\u00e0 de la Salut, Barcelona, Spain"},{"name":"CIBERDEM, Madrid, Community of Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Regidor","sequence":"additional","affiliation":[{"name":"CIBERESP, Madrid, Community of Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"2025092219301610000_15.9.e106069.1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","article-title":"Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends","volume":"10","author":"Khan","year":"2020","journal-title":"J Epidemiol Glob Health"},{"key":"2025092219301610000_15.9.e106069.2","unstructured":"International Diabetes Federation . IDF Diabetes Atlas-10th Edition, 2021. Available: www.diabetesatlas.org [Accessed 8 Jul 2025]."},{"key":"2025092219301610000_15.9.e106069.3","unstructured":"Base de datos cl\u00ednicos de Atenci\u00f3n Primaria (BDCAP). Statistical Site of NHS . Statistical Site of NHS, Available: https:\/\/pestadistico.inteligenciadegestion.sanidad.gob.es\/publicoSNS\/S\/base-de-datos-de-clinicos-de-atencion-primaria-bdcap [Accessed 10 Apr 2025]."},{"key":"2025092219301610000_15.9.e106069.4","unstructured":"Base de datos cl\u00ednicos de Atenci\u00f3n Primaria (BDCAP) . Caracterizaci\u00f3n de problemas de salud no transmisibles a partir de los registros cl\u00ednicos de atenci\u00f3n primaria, Available: https:\/\/www.sanidad.gob.es\/estadEstudios\/estadisticas\/estadisticas\/estMinisterio\/SIAP\/home [Accessed 10 Apr 2025]."},{"key":"2025092219301610000_15.9.e106069.5","doi-asserted-by":"crossref","first-page":"155332","DOI":"10.1016\/j.metabol.2022.155332","article-title":"Pharmacotherapy of type 2 diabetes: An update and future directions","volume":"137","author":"DeMarsilis","year":"2022","journal-title":"Metab Clin Exp"},{"key":"2025092219301610000_15.9.e106069.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925"},{"key":"2025092219301610000_15.9.e106069.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1616011"},{"key":"2025092219301610000_15.9.e106069.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31150-X"},{"key":"2025092219301610000_15.9.e106069.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32590-X"},{"key":"2025092219301610000_15.9.e106069.10","article-title":"Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis","volume":"10","author":"Kanie","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2025092219301610000_15.9.e106069.11","doi-asserted-by":"crossref","unstructured":"Higgins V , Piercy J , Roughley A , et al . doi:10.2147\/DMSO.S120101 DMSO 2016;Volume 9:371\u201380. 10.2147\/DMSO.S120101.","DOI":"10.2147\/DMSO.S120101"},{"key":"2025092219301610000_15.9.e106069.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa2032271"},{"key":"2025092219301610000_15.9.e106069.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2020.12.015"},{"key":"2025092219301610000_15.9.e106069.14","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/dom.13877","article-title":"Trends in antidiabetic drug utilization and expenditure in Denmark: A 22-year nationwide study","volume":"22","author":"Bang","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"2025092219301610000_15.9.e106069.15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.puhe.2017.06.008","article-title":"Prescription trends and the selection of initial oral antidiabetic agents for patients with newly diagnosed type 2 diabetes: a nationwide study","volume":"152","author":"Liu","year":"2017","journal-title":"Public Health (Fairfax)"},{"key":"2025092219301610000_15.9.e106069.16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2022-002995","article-title":"Treatment pattern trends of medications for type 2 diabetes in British Columbia, Canada","volume":"10","author":"Carney","year":"2022","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2025092219301610000_15.9.e106069.17","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022768","article-title":"Changing use of antidiabetic drugs in the UK: trends in prescribing 2000\u20132017","volume":"8","author":"Wilkinson","year":"2018","journal-title":"BMJ Open"},{"key":"2025092219301610000_15.9.e106069.18","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13636"},{"key":"2025092219301610000_15.9.e106069.19","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.clinthera.2025.02.005","article-title":"Antidiabetic Drugs Consumption in France Over a Decade: An Observational Study","volume":"47","author":"David","year":"2025","journal-title":"Clin Ther"},{"key":"2025092219301610000_15.9.e106069.20","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1144"},{"key":"2025092219301610000_15.9.e106069.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00537-3"},{"key":"2025092219301610000_15.9.e106069.22","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes","volume":"45","author":"Davies","year":"2012","journal-title":"Diabetes Care"},{"key":"2025092219301610000_15.9.e106069.23","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-S009"},{"key":"2025092219301610000_15.9.e106069.24","first-page":"81","article-title":"Caracter\u00edsticas basales de los primeros pacientes incluidos en el estudio PRECOZIN","volume":"15","author":"Cea-Soriano","year":"2024","journal-title":"Diabetes Pr\u00e1ctica"},{"key":"2025092219301610000_15.9.e106069.25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099773","article-title":"Treatment pattern of type 2 diabetes differs in two German regions and with patients\u2019 socioeconomic position","volume":"9","author":"Tamayo","year":"2014","journal-title":"PLoS One"},{"key":"2025092219301610000_15.9.e106069.26","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-54856-6","article-title":"Trends in diabetes prevalence, awareness, treatment, and control in French-speaking Switzerland","volume":"14","author":"Pauli","year":"2024","journal-title":"Sci Rep"},{"key":"2025092219301610000_15.9.e106069.27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0313988","article-title":"Socioeconomic inequalities in the prevalence, non-awareness, non-treatment, and non-control of diabetes among South Korean adults in 2021","volume":"19","author":"Kim","year":"2024","journal-title":"PLoS ONE"},{"key":"2025092219301610000_15.9.e106069.28","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.2337\/dc23-S009","article-title":"9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes\u20142023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"2025092219301610000_15.9.e106069.29","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12417"},{"key":"2025092219301610000_15.9.e106069.30","first-page":"247","article-title":"Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes","volume":"77","author":"Bianchi","year":"2017","journal-title":"Drugs (Abingdon Engl)"},{"key":"2025092219301610000_15.9.e106069.31","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.clinthera.2023.07.026","article-title":"Metformin and SGLT2i as First-line Combination Therapy in Type 2 Diabetes: A Real-world Study With a Focus on Ethnicity","volume":"45","author":"Anson","year":"2023","journal-title":"Clin Ther"},{"key":"2025092219301610000_15.9.e106069.32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1179551418786258","article-title":"Combination of Empagliflozin and Metformin Therapy: A Consideration of its Place in Type 2 Diabetes Therapy","volume":"11","author":"Goldman","year":"2018","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"2025092219301610000_15.9.e106069.33","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/dom.14226","article-title":"Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes","volume":"23","author":"Neuen","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2025092219301610000_15.9.e106069.34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.endinu.2022.06.009","article-title":"GALIPDIA study: Reaching lipid targets in a population with type 2 diabetes (T2DM) from the Northwest of Spain","volume":"70","author":"Villar-Taibo","year":"2023","journal-title":"Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n"},{"key":"2025092219301610000_15.9.e106069.35","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/jdi.12625","article-title":"Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: A meta-analysis","volume":"8","author":"Cai","year":"2017","journal-title":"J Diabetes Investig"},{"key":"2025092219301610000_15.9.e106069.36","first-page":"219","article-title":"Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity","volume":"79","author":"Pereira","year":"2019","journal-title":"Drugs (Abingdon Engl)"},{"key":"2025092219301610000_15.9.e106069.37","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-019-0822-4","article-title":"Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group","volume":"18","author":"Schnell","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"2025092219301610000_15.9.e106069.38","doi-asserted-by":"crossref","first-page":"92","DOI":"10.17925\/EE.2021.17.2.92","article-title":"Changing the Concept: From the Traditional Glucose-centric to the New Cardiorenal-metabolic Approach for the Treatment of Type 2 Diabetes","volume":"17","author":"Chatzis","year":"2021","journal-title":"touchREVIEWS in Endocrinology"},{"key":"2025092219301610000_15.9.e106069.39","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S2213-8587(24)00242-0","article-title":"Younger-onset compared with later-onset type 2 diabetes: an analysis of the UK Prospective Diabetes Study (UKPDS) with up to 30 years of follow-up (UKPDS 92)","volume":"12","author":"Lin","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025092219301610000_15.9.e106069.40","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/dom.14192","article-title":"Early combination therapy delayed treatment escalation in newly diagnosed young-onset type 2 diabetes: A subanalysis of the VERIFY study","volume":"23","author":"Chan","year":"2021","journal-title":"Diabetes Obes Metab"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-106069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:46:56Z","timestamp":1758638816000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-106069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,22]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1136\/bmjopen-2025-106069"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-106069","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]}}}